Reference number : 172-2024-2025-Q2-1019260, amendment number : , agreement type : C, recipient legal name : CereCura Nanotherapeutics Inc., recipient country : CA, recipient province : BC, recipient city : Vancouver|Vancouver, recipient postal code : V6B 0M3, program name english : Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives, program name french : Programme de collaboration en science, en technologie et en innovation - Initiatives de collaboration en R-D, program purpose english : Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas., program purpose french : Collaborer à des programmes multipartites de recherche-développement dans le but de profiter de la synergie entre la recherche transformatrice à haut risque et à haut rendement et le potentiel de découvertes scientifiques et de percées technologiques révolutionnaires dans des secteurs d’intervention prioritaires., agreement title english : In situ protein manufacturing: systemic LNP-RNA to deliver therapeutic proteins to the brain., agreement title french : Fabrication de protéines in situ : l’ARN sous forme de nanoparticule lipidique, dans la circulation générale, pour diffuser des protéines thérapeutiques dans l’encéphale, agreement number : 1019260, agreement value : 84564.0, agreement start date : 2024-09-20, agreement end date : 2026-03-31, description english : Neurological disorders affect up to 10% of Canadians, and few treatment options exist. Current understanding of disease pathogenesis suggests that protein replacement or supplementation is an attractive therapeutic approach. However, the development of protein biologics for the brain is marred by two key problems: spatial distribution across the BBB and short protein half-lives. The project will investigate the delivery of protein biologics to the brain using an in situ ‘Bioreactor’ approach. Using lipid nanoparticles encapsulating messenger RNA (LNP-mRNA), a subset of brain cells are instructed to produce and secrete therapeutic proteins continually over the lifespan of stably-modified RNA. Using LNPs that cross the BBB, this unique bioreactor approach could deliver proteins with brain-wide diffusion. This approach only requires limited cell transfection rate, has low cell-specific tropism requirements, and can be adapted to produce proteins for different indications. It therefore represents a platform-enabling translatable strategy for novel nanomedicines for a range of neurological diseases., description french : Fabrication de protéines in situ : l’ARN sous forme de nanoparticule lipidique, dans la circulation générale, pour diffuser des protéines thérapeutiques dans l’encéphale, expected results english : In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems., expected results french : À court terme, les résultats prévus seront des collaborations renforcées entre l'industrie, le milieu universitaire et le gouvernement pour soutenir l'excellence en recherche. À moyen terme, les résultats attendus seront le développement de nouvelles technologies potentiellement perturbatrices avec des collaborateurs. À long terme, trouver des solutions collaboratives aux défis des politiques publiques et créer des systèmes d'innovation plus solides., additional information english : nan, additional information french : nan, owner organization : nrc-cnrc, owner organization title : National Research Council Canada | Conseil national de recherches Canada